Seeking Alpha

Novo Nordisk (NVO -2.1%) shares slip after announcing the FDA extended the regulatory review...

Novo Nordisk (NVO -2.1%) shares slip after announcing the FDA extended the regulatory review period by three months for the drug maker's ultra-long-acting insulins degludec and insulin degludec/insulin aspart for the treatment of type 1 and type 2 diabetes.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs